Aripiprazole in the treatment of the psychosis prodrome

British Journal of Psychiatry - Tập 191 Số S51 - Trang s96-s101 - 2007
Scott W. Woods1, Elizabeth M. Tully1, Barbara C. Walsh1, Keith A. Hawkins1, Jennifer L. Callahan1, Shuki J. Cohen1, Daniel H. Mathalon1, Tandy J. Miller2, Thomas H. McGlashan1
1Yale University School of Medicine, New Haven, Connecticut, USA.
2University of New Mexico School of Medicine, Albuquerque, New Mexico, USA

Tóm tắt

BackgroundResearch studies for the treatment of the putative prodromal phase of psychotic disorders have begun to appearAimsTo obtain preliminary evidence of the short-term efficacy and safety of aripiprazole treatment in people with the psychosis prodromeMethodFifteen participants meeting prodrome criteria (mean age 17.1 years, s.d.=5.5) enrolled in an open-label, single-site trial with fixed-flexible dosing of aripiprazole (5–30 mg/day) for 8 weeksResultsIn the mixed-effects repeated-measures analysis, improvement from baseline on the Scale of Prodromal Symptoms total score was statistically significant by the first week. No participant converted to psychosis and 13 completed treatment. Neuropsychological measures showed no consistent improvement; mean weight gain was 1.2 kg. Akathisia emerged in 8 participants, but the mean Barnes Akathisia Scale score fell to baseline levels by the final visit. Adverse events were otherwise minimalConclusionsAripiprazole shows a promising efficacy and safety profile for the psychosis prodrome. Placebo-controlled studies are indicated

Từ khóa


Tài liệu tham khảo

10.1016/S0006-3223(03)00321-4

Woods, 2001, The prodromal patient: both symptomatic and at risk, CNS Spectrums, 6, 223, 10.1017/S1092852900008609

10.4088/JCP.v64n0607

10.1176/ajp.84.1.105

Spreen, 1998, A Compendium of Neuropsychological Tests: Administration, norms, and commentary

10.1111/j.1600-0447.1970.tb02066.x

Rey, 1964, L'examen clinique en psychologique

10.1001/archpsyc.62.9.961

10.1192/bjp.185.4.291

10.1016/S0920-9964(02)00440-1

10.1093/oxfordjournals.schbul.a007040

10.1176/appi.ajp.159.5.863

10.1023/A:1022034115078

10.1001/archpsyc.59.10.921

10.1016/S0920-9964(03)00050-1

Levine, 1986, Strategies for analyzing side-effect data from SAFTEE – a workshop held Fall 1985 in Rockville, Maryland, Psychopharmacology Bulletin, 22, 343

10.1007/s00213-006-0428-x

10.1093/schbul/10.3.388

10.1155/2004/940191

10.1016/S0033-3182(95)71666-8

10.1080/01688638308401171

Findling, 2004, Pharmacokinetic effects of aripiprazole in children and adolescents with conduct disorder, International Journal of Neuropsychopharmacology, 7, S440

Falloon, 1992, Early intervention for first episodes of schizophrenia: a preliminary exploration, Psychiatry, 55, 4, 10.1080/00332747.1992.11024572

10.1016/0165-1781(88)90076-5

10.1124/jpet.102.033175

Branch, 1975, Abnormal involuntary movement scale (AIMS), Early Clinical Drug Evaluation Unit Intercom, 4, 3

10.1016/S0920-9964(03)00053-7

Bleuler, 1911, Dementia Praecox or the Group of the Schizophrenias

10.1192/bjp.157.6.853

10.1037/0022-006X.56.6.893

10.1192/bjp.154.5.672

10.1192/bjp.133.5.429

10.1176/appi.ps.53.3.342

Heaton, 1993, Wisconsin Card Sorting Test, Manual

10.1016/S0920-9964(99)00015-8

1994, Diagnostic and Statistical Manual of Mental Disorderes

10.1016/S0920-9964(03)80436-X

Spreen, 1969, Neurosensory Center Comprehensive Examination for Aphasia (NCCEA)

10.1016/0920-9964(90)90005-R

Yung, 1998, Prediction of psychosis. A step towards indicated prevention of schizophrenia, British Journal of Psychiatry, 72, 14, 10.1192/S0007125000297602

10.1016/j.schres.2003.08.007

10.1176/ajp.2006.163.5.790

Thông tin
Thông tin xuất bản

British Journal of Psychiatry

Tập 191 Số S51

s96-s101

Thông tin tác giả